Frank NAMUGERA
ID:
|
Adoption and sustained use of efficient energy-saving technology (firewood cooking stoves) in Rwampara district, rural western Uganda.
REFNo: SS1346ES
To assess the impact of the adoption of improved cookstoves in communities near Bugamba forest, Rwampara District in western Uganda.
Specific objectives:
1. To assess the knowledge, attitudes and practices of households towards energy consumption and quality of life in areas around Bugamba forest.
2. To assess the behavioral change patterns of individuals following the construction of the improved cookstoves.
3. To assess the changes in the quality of life of the communities after the adoption of the ICS.
4. To ascertain the impact of the adoption of clean energy cooking on the environment in the communities near Bugamba forest.
|
Uganda |
2022-07-25 11:14:17 |
2025-07-25 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
PRISCILLA KASEMBO
ID:
|
REPORTED ADVERSE DRUG REACTIONS OF ANTIRETROVIRAL THERAPY GENERIC FORMULATIONS IN UGANDA
REFNo: HS2042ES
1.To assess the reported adverse drug reactions of the first line ART generic formulations containing Tenofovir, Lamivudine and Efavirenz or Dolutegravir (TDF/3TC/EFV or DTG)in Uganda.
2.To document the reported ADRs of the first line ART generic formulations containing TDF/3TC/EFV or DTG at National Pharmacovigilance Center, Kisenyi HC4, Kiswa HC 3 and Mildmay hospital in Uganda
3.To compare ADR profiles by severity between different ART generic formulations containing TDF/3TC/EFV or DTG.
4. To compare the ADR profile between the two first line ART regimens (DTG and EFV based generic formulations).
5. To explore ADR reporting among health workers at Kisenyi HC4, Kiswa HC 3 and Mildmay hospital in Uganda, in reference to particular first line ART generic formulations (TDF/3TC/EFV or DTG).
|
Uganda |
2022-07-22 15:00:41 |
2025-07-22 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Winny Akullo Nekesa
ID:
|
Adoption of Linked Data among University libraries in Uganda
REFNo: SS1338ES
The study will address the following specific objectives:
1. Determine the level of awareness of Linked Data among the professional librarians in Ugandan Universities.
2. Establish the extent of Linked Data adoption in Ugandan Universities.
3. Determine the potential benefits of adopting Linked Data in Ugandan Universities.
4. Investigate the factors that influence the professional librarians’ behaviour towards the adoption of Linked Data in Ugandan Universities.
5. Investigate the strategies to promote the adoption of Linked Data in Ugandan Universities.
|
Uganda |
2022-07-21 11:01:06 |
2025-07-21 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
REFNo: HS2173ES
8. To validate the ability of fertility biomarkers to diagnose and predict permanent loss of ovarian function, and to determine the impact of anti-cancer therapy on hormone levels,7. To evaluate health status utility scores of patients treated with atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine,6. To identify and/or evaluate biomarkers that are predictive of response to atezolizumab and trastuzumab emtansine (i.e., predictive biomarkers), are early surrogates of efficacy, are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with acquired resistance to atezolizumab and trastuzumab emtansine, are associated with susceptibility to developing adverse events or can lead to improved adverse event monitoring or investigation (i.e., safety biomarkers), can provide evidence of atezolizumab and trastuzumab emtansine activity (i.e., pharmacodynamic biomarkers), or can increase the knowledge and understanding of disease biology and drug safety,5. To evaluate the immune response to atezolizumab and trastuzumab emtansine,4. To characterize the PK profiles of atezolizumab and trastuzumab emtansine when given in combination,3. To evaluate the safety of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine,2. To evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in the PRO-evaluable analysis set,1. The secondary efficacy objective for this study is to evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in both the ITT population and PD-L1-positive population,The primary objective for this study is to evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in both the ITT population (all comers) and the PD-L1-positive population (defined as all patients from the ITT population with a centrally assessed PD-L1-positive status [i.e., PD-L1 status of IC1/2/3] at randomization),
|
Uganda |
2022-07-21 11:00:02 |
2025-07-21 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Sonia Michaelsen Ingrid
ID:
|
Sexual and gender-based violence against South Sudanese Refugees in Uganda: A mixed-methods case study
REFNo: SS1029ES
The overall objective is to explore and compare the perceptions and experiences of sexual and gender-based violence (SGBV) towards South Sudanese refugees in Uganda who live in designated settlements to those who self-settled. More specifically:
1.To estimate the prevalence of SGBV among South Sudanese refugees in Ugandan settlements vs. those who have self-settled in urban areas
2.To identify the risk and protective factors of SGBV amongst South Sudanese refugees in designated settlements vs. urban areas, from the perspective of South Sudanese refugees and local community leaders and decision makers
3.To explore the relationship between the estimated prevalence of SGBV in settlements and urban areas and the risk and protective factors identified by participants
4.To generate context-dependent, stakeholder-led solutions to reduce SGBV in each setting
|
Canada |
2022-07-21 10:50:50 |
2025-07-21 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|